Skip to content

Agios Pharmaceuticals AGIO Lease Liability Payments - 2021

Lease Liability Payments - 2021 at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$1.05M-29.4%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$18.11M+10.1%

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's lease liability payments - 2021.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's lease liability payments - 2021?
Agios Pharmaceuticals (AGIO) reported lease liability payments - 2021 of $394K in Q1 2026.
What does lease liability payments - 2021 mean?
This metric captures the total contractual cash payments due for operating and finance leases specifically during the 2021 fiscal period. It serves as a historical or forward-looking benchmark for lease-related cash outflows. It is used by analysts to model the company's fixed cost structure and cash flow requirements.